Drug Profile
Research programme: anti-hypertensive therapy - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class Heterocyclic compounds
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in USA (PO)
- 05 Aug 2009 Preclinical development is ongoing in USA
- 10 Apr 2006 Preclinical trials in Hypertension in USA (PO)